# To evaluate whether intravenous Adenosine would replace the need for inhaled nitric oxide (iNO) in the management of Persistent Pulmonary Hypertension of the Newborn (PPHN)

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
30/09/2004		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
30/09/2004	Completed	[X] Results		
<b>Last Edited</b> 08/07/2009	<b>Condition category</b> Neonatal Diseases	[] Individual participant data		

# Plain English summary of protocol

Not provided at time of registration

## Contact information

# Type(s)

Scientific

### Contact name

Dr CM Pierce

### Contact details

PICU
Great Ormond Street Hospital
Great Ormond Street
London
United Kingdom
WC1N 3JH

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

### Secondary identifying numbers

N0012128264

# Study information

### Scientific Title

### **Study objectives**

Can Adenosine replace nitric oxide in the treatment of PPHN?

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

## Health condition(s) or problem(s) studied

Neonatal Diseases: Persistant pulmonary hypertension

### **Interventions**

- 1. Intravenous adenosine
- 2. No adenosine

### Intervention Type

Drug

### Phase

**Not Specified** 

### Drug/device/biological/vaccine name(s)

Adenosine

### Primary outcome measure

Whether Adenosine can replace or supplement the use of iNO in the treatment of PPHN.

### Secondary outcome measures

Not provided at time of registration

### Overall study start date

01/12/2002

### Completion date

30/11/2003

# **Eligibility**

### Key inclusion criteria

Neonates with PPHN requiring mechanical ventilation and inhaled nitric oxide at 20 parts per million

### Participant type(s)

**Patient** 

### Age group

Neonate

### Sex

**Not Specified** 

### Target number of participants

9

### Key exclusion criteria

Does not meet inclusion criteria

### Date of first enrolment

01/12/2002

### Date of final enrolment

30/11/2003

# Locations

### Countries of recruitment

England

**United Kingdom** 

### Study participating centre

### PICU London United Kingdom WC1N 3JH

# **Sponsor information**

### Organisation

Department of Health

### Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

### Sponsor type

Government

### Website

http://www.dh.gov.uk/Home/fs/en

# Funder(s)

### Funder type

Hospital/treatment centre

### **Funder Name**

Great Ormond Street Hospital for Children NHS Trust (UK)

### **Funder Name**

Institute of Child Health (UK)

# **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

Intention to publish date

# Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration

# Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2004		Yes	No